Skip to main content
Fig. 2 | Cancer & Metabolism

Fig. 2

From: Safety, tolerability, and effectiveness of the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in combination with standard chemotherapy for patients with advanced, inoperable pancreatic adenocarcinoma: a phase 1b observational study

Fig. 2

Changes in plasma metabolic chemistry following dapagliflozin treatment. Fasting metabolic lab values were obtained of A glucose, B b-hydroxybutyrate ketone, C anion gap, an indirect measurement of plasma ketoacids, D glucagon, E C-peptide (a marker for endogenous insulin), and F and pancreatic polypeptide were measured at the first day of treatment (day 1) and the 15th day of the second cycle of treatment (day 43). Paired t tests across patients showed only a significant increase in glucagon

Back to article page

Cancer & Metabolism

ISSN: 2049-3002